TCI Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

TCI Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,630	Closed	-$4K	–	2204
2021 Q4	$4K	Buy	+1,630	New	+$4.45K	﹤0.01%	1770
2021 Q3	–	Sell	-843	Closed	-$3K	–	2366
2021 Q2	$3K	Buy	843 +305	+57%	+$1.03K	﹤0.01%	1691
2021 Q1	$2K	Buy	+538	New	+$1.94K	﹤0.01%	1647

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OCM

Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

TCI Wealth Advisors's AKBA Position: Q1 2022 in Review

TCI Wealth Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 1,630 shares — an estimated $4K sold.

TCI Wealth Advisors first reported a position in AKBA in Q1 2021 and held it in 3 quarters. The position peaked at $4K in Q4 2021. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

TCI Wealth Advisors reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
TCI Wealth Advisors sold 1,630 Akebia Therapeutics shares in Q1 2022, an estimated $4K.
TCI Wealth Advisors first reported a position in Akebia Therapeutics in Q1 2021 and held it in 3 quarters.
TCI Wealth Advisors's Akebia Therapeutics position peaked at $4K in Q4 2021.
124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on TCI Wealth Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.